Not Yet RecruitingPhase 3ACTRN12605000680662
Safety and Tolerability Study of the JE Vaccine IC51
Safety and Tolerability of the Japanese Encephalitis Vaccine IC51(JE-PIV).
Sponsor
Intercell AG
Enrollment
600 participants
Start Date
Oct 12, 2006
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and femalesMin Age: 18 Yearss
Plain Language Summary
Simplified for easier understanding
This study evaluates the safety and tolerability of a Japanese encephalitis vaccine called IC51. Healthy adults aged 18 and older may be eligible. Participants would receive the vaccine and be monitored for any side effects over a period of time through check-ups and blood tests.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A double-blind, randomized controlled Phase III study to investigate the safety and the tolerability of the JE vaccine IC51.The duration of the treatment including a follow-up period is 56 days.
A double-blind, randomized controlled Phase III study to investigate the safety and the tolerability of the JE vaccine IC51.The duration of the treatment including a follow-up period is 56 days.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000680662